

DOCKET NO.: ISIS-3510 (ISIC-0001-102)

PATENT

wherein said antisense oligonucleotide modulates expression of a cellular adhesion protein, modulates a rate of cellular proliferation, or has biological activity against eukaryotic pathogens or retroviruses.

REMARKS


The Office Action requests clarification of the amendment to claim 1 submitted on February 27, 2003 ("H"), indicating that the claim appears to lack certain language set forth in amendment "E" of February 1, 2002 without instructions to make such a deletion. Applicants wish to clarify that the some claim language set forth in amendment "E" was inadvertently omitted in amendment "H." The corrected amendment "H" is set forth herein.

Thus, upon entry of the amendments, claims 1, 4-7, 10, 12, 13, 15, 17, 19, 20, 80, 84, 85, and 87-96 are pending in this application. Claim 1 has been amended. Claims 87-96 are new. No new matter has been added.

In view of the foregoing, Applicant submits that the claims as amended are in condition for allowance, and an early Office Action to that effect is earnestly solicited.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Respectfully submitted,


Christine A. Goddard, Ph.D.
Registration No. 46,731

Date: June 9, 2003

COZEN O'CONNOR
1900 Market Street
Philadelphia, PA 19103
(215) 665-2191 (phone)
(215) 701-2191 (fax)

RECEIVED
JUN 13 2003
TECH CENTER 1600/2900

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Please amend claim 1 as provided below.

1. (amended three times) A composition in dosage form suitable for non-parenteral administration comprising at least one antisense oligonucleotide in an emulsion and at least one penetration enhancer selected from the group consisting of surfactants, fatty acids, bile salts, chelating agents, non-chelating non-surfactant molecules, and combinations thereof;

wherein said non-chelating non-surfactant is selected from the group consisting of unsaturated cyclic ureas, 1-alkyl-alkanones, 1-alkenylazacyclo-alkanones, non-steroidal anti-inflammatory agents, and combinations thereof;

wherein said antisense oligonucleotide modulates expression of a cellular adhesion protein, modulates a rate of cellular proliferation, or has biological activity against eukaryotic pathogens or retroviruses.